Drug Trial Radar · NCT01772004
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
Last checked: Nov 20, 2026Latest source record: Dec 20, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,756
Actual
Start
Jan 31, 2013
Primary completion
Dec 16, 2019
Study completion Dec 16, 2019
Sponsor
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Merck KGaA, Darmstadt, Germany
- First posted
- Jan 21, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1, open-label, dose-escalation trial of avelumab \[antibody targeting programmed death ligand 1 (anti PD-L1)\] with consecutive parallel group expansion in participants with selected tumor indications. New recruitment is open for all active cohorts. Active cohorts: Escalation revised dosing regimen cohort. Closed cohorts: Non-small cell lung cancer (NSCLC, first line), NSCLC (post-platinum), metastatic breast cancer (MBC), colorectal cancer (CRC), urothelial carcinoma (secondary), mesothelioma, gastric/GEJ cancer (first line switch maintenance and second line), and ovarian cancer (secondary and platinum refractory + liposomal doxorubicin), renal cell carcinoma (second line) melanoma and head, neck squamous cell carcinoma (HNSCC), castrate-resistant prostate cancer (CRPC), adrenocortical carcinoma (ACC) urothelial carcinoma (efficacy), gastric/gastroesophageal junction (GEJ) cancer (third line), renal cell carcinoma (RCC, first line) and escalation phase .
Conditions
- Solid Tumors
Interventions
AvelumabDrug
Participants received intravenous infusion of Avelumab in dose escalation and expansion cohorts until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Escalation Cohort (Excluding Once Weekly Avelumab 10 mg/kg Cohort): Number of Participants Experiencing Dose Limiting Toxicities (DLTs)Time frame: Dose Escalation: Baseline up to Week 3
- Efficacy Expansion Cohort (Ovarian Cancer): Number of Participants With Confirmed Best Overall Response (BOR) as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), as Adjudicated by Independent Endpoint Review Committee (IERC)Time frame: Ovarian Cancer Efficacy Expansion: Baseline up to Day 620
- Efficacy Expansion Cohort(Urothelial Carcinoma): Number of Participants With Confirmed Best Overall Response (BOR) as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), as Adjudicated by Independent Endpoint Review Committee (IERC)Time frame: Urothelial Carcinoma Efficacy Expansion: Baseline up to Day 931
- Efficacy Expansion Cohort (GC/GEJC, Third Line): Number of Participants With Confirmed Best Overall Response (BOR) as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), as Adjudicated by Independent Endpoint Review Committee (IERC)Time frame: GC/GEJC, Third Line Efficacy Expansion: Baseline up to Day 871
- Efficacy Expansion Cohort (HNSCC): Number of Participants With Confirmed Best Overall Response (BOR) as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), as Adjudicated by Independent Endpoint Review Committee (IERC)Time frame: HNSCC Efficacy Expansion: Baseline up to Day 1072
Locations
74 sites in 9 countries. Site status is shown where the registry gives one.
Cancer Treatment Centers of America - Western Regional Medical Center
Goodyear, Arizona
Scottsdale Healthcare Corporation
Scottsdale, Arizona
Pinnacle Oncology Hematology
Scottsdale, Arizona
Highlands Oncology Group
Rogers, Arkansas
Pacific Cancer Medical Center, Inc.
Anaheim, California
California Cancer Associates for Research & Excellence, Inc
Encinitas, California
Healing Hands Oncology and Medical Care
Inglewood, California
Scripps Health dba Scripps Clinical Research Services
La Jolla, California
The Angeles Clinic and Research Institute - West LA
Los Angeles, California
Cedars-Sinai Medical Center - Oncology
Los Angeles, California
University of California Davis Health System
Sacramento, California
Sharp Memorial Hospital
San Diego, California
Georgetown University Medical Center- Research Parent
Washington D.C., District of Columbia
Holy Cross Hospital
Fort Lauderdale, Florida
University of Miami
Miami, Florida
Hematology - Oncology Associates of Treasure Coast - Hematology-Oncology Associates of Treasure Coast
Port Saint Lucie, Florida
Florida Cancer Specialists
Sarasota, Florida
Northeast Georgia Cancer Care, LLC
Athens, Georgia
Peachtree Hematology-Oncology Consultants, PC
Atlanta, Georgia
Augusta University - formerly Georgia Regents University
Augusta, Georgia
Northwest Georgia Oncology Centers PC
Marietta, Georgia
University of Chicago Medical Center
Chicago, Illinois
Horizon Oncology Research, INC
Lafayette, Indiana
The Johns Hopkins Hospital
Baltimore, Maryland
RCCA MD LLC - Bethesda
Bethesda, Maryland
National Cancer Institute
Bethesda, Maryland
Maryland Oncology Hematology, P.A.
Rockville, Maryland
Karmanos Cancer Institute
Detroit, Michigan
Henry Ford Medical Center
Detroit, Michigan
Michigan State University
Lansing, Michigan
Virginia Piper Cancer Institute
Minneapolis, Minnesota
Kansas City Research Institute, LLC - Phase I Unit
Kansas City, Missouri
Washington University in St. Louis
St Louis, Missouri
San Juan Oncology Associates
Farmington, New Mexico
Columbia University College of Phys & Surgeons
New York, New York
Montefiore Medical Center PRIME
The Bronx, New York
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Carolina BioOncology Institute, LLC - Cancer Therapy and Research Center
Huntersville, North Carolina
UC Health Clinical Trials Office
Cincinnati, Ohio
University Hospitals Case Medical Center - Case Comprehensive Cancer Center
Cleveland, Ohio
Showing 40 of 74 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.